This one is really interesting. A ton of good clinical evidence is building on it, trials happening, and lots of strong anecdotal support from the medical community. Low risk, low (relative) cost. This was a good documentary: <iframe width="300" height="215" src="https://www.youtube-nocookie.com/embed/4ITbNDgFofY" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe> [Immunetherapeueutics.com PDF](https://www.immunetherapeutics.com/wp-content/uploads/2014/10/Immune_Therapeutics_Low_Dose_Naltrexone_Fact-Sheet_for_Doctors-.pdf) [Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy - PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10968813/) Conclusions The current state of knowledge regarding the use of LDN in cancer treatment indicates that this drug has high therapeutic potential, particularly as an adjuvant for both traditional chemotherapy and new treatment methods, such as immunotherapy. [Full article: Naltrexone at low doses (LDN) and its relevance to cancer therapy](https://www.tandfonline.com/doi/full/10.1080/14737140.2022.2037426) Considering the increase in the number of anecdotal reports of activity, there will likely be a bigger drive toward using LDN in the oncological setting. These reports support clinical trials of LDN in cancer, especially when given in combination with certain chemotherapy.